News of Note—Vical, FluGen and more

In this week's news of note, Vical announced a restructuring. (Pixabay)

Here's some other vaccine news of note for the week:

> After its Astellas-partnered CMV vaccine failed a late-stage trial last week, Vical announced it's laying off 40 employees and focusing its efforts on an HSV-2 vaccine candidate and an antifungal drug. FierceBiotech story | More

> FluGen is planning a new study in Europe for its universal flu vaccine candidate. Wisconsin State Journal article

> The University of Tokyo entered a cancer vaccine partnership with the Kanagawa Cancer Center and BrightPath Biotherapeutics. Release

Suggested Articles

BN will use its proprietary MVA-BN platform to develop a vaccine against three strains of the potentially deadly mosquito-borne virus.

BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.

The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.